Pharmaceutical

Opinion: Congress can eradicate hepatitis C and reduce ...

The initiative comes with a $12.3 billion price tag — and over 10 years, the sav...

STAT+: With momentum on Alzheimer’s therapies, Europe s...

With momentum on Alzheimer’s therapies, Europe sees delivery challenges ahead, too.

In N.C., Mandy Cohen built bridges to GOP. Can she find...

In N.C., Mandy Cohen built bridges to the GOP. Can she find consensus as the new...

STAT+: Why hospitals are cutting ties with Moody’s rati...

Over the past roughly 18 months, Moody’s ratings have been withdrawn on nearly $...

STAT+: Medicare eyes cuts to doctors, raises to outpati...

“This is almost biblical in its impact,” Jesse Ehrenfeld, an anesthesiologist an...

WHO says aspartame might cause cancer — but that most a...

Aspartame, the popular artificial sweetener in diet sodas and chewing gums, may ...

STAT+: House panel passes public health bills following...

Lawmakers passed bills on pandemic preparedness and allowing the Senate retroact...

STAT+: Caribou posts encouraging durability results on ...

Caribou Biosciences said its off-the-shelf CART-T therapy induced durable, compl...

STAT+: How a key Senate committee is planning to regula...

A key Senate health care panel has developed a plan to tackle reforms to middlem...

After FDA nod, Better Therapeutics races to boost dwind...

In the latest edition of STAT's Health Tech newsletter: Better Therapeutics race...

Listen: Wegovy in the brain, pivotal Alzheimer’s data, ...

Is Wegovy really a brain drug? Which Alzheimer's disease treatment works best? A...

Celiac study examines precisely how gluten triggers inj...

A new study of celiac disease offers a possible explanation for how gluten can s...

J&J expands global access to TB drug as popular novelis...

Johnson & Johnson expanded global access to tuberculosis drug this week amid nov...

STAT+: Demand spikes in seniors, behavioral health care...

UnitedHealth Group’s provider arm struggled in the second quarter as more senior...

Atrial fibrillation market set to decline at a CAGR of ...

Atrial fibrillation drugs' patent expiration is largely responsible for the pred...

HTA outcomes in the 5EU are growing at 27% with a deep ...

GlobalData has analysed HTA decisions made for branded medicines in 5EU from 201...